Anamorelin Research: What 178 Studies Show (2026) | RetatrutideCompare

Anamorelin — 178 studies indexed on PubMed. Oral GHS-R1a agonist that stimulates appetite, GH/IGF-1 axis and lean body mass. Half-life: ~7 hours. FDA status: Approved Japan (Adlumiz, 2021); FDA CRL 2017.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Anamorelin?

There are approximately 178 studies indexed on PubMed that mention Anamorelin (ONO-7643, RC-1291), based on a search last updated 2026-06-18.

Is Anamorelin FDA-approved?

FDA status: Approved Japan (Adlumiz, 2021); FDA CRL 2017.

How does Anamorelin work?

Oral GHS-R1a agonist that stimulates appetite, GH/IGF-1 axis and lean body mass.

Oral GHS-R1a agonist that stimulates appetite, GH/IGF-1 axis and lean body mass.

Reference facts

Also known as
ONO-7643, RC-1291, Adlumiz
Category
Growth Hormone & Ghrelin
Mechanism of action
Oral GHS-R1a agonist that stimulates appetite, GH/IGF-1 axis and lean body mass.
Targets
GHS-R1a
Indications under research or approved
Cancer cachexia (NSCLC, gastric, pancreatic, colorectal)
Regulatory status (reference entry)
Approved Japan (Adlumiz, 2021); FDA CRL 2017
Half-life
~7 hours
Sequence notes
Orally active peptidomimetic ghrelin receptor agonist (small molecule with peptide-mimetic backbone).
Molecular weight (Da)
547
Originator / sponsor
Helsinn / Ono
First reported
2003

Primary References

Explore research articles about Anamorelin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.